Thomas joined Definiens as CEO in 2004 and has guided Definiens to become the global leader in Tissue Phenomics. With the acquisition of Definiens by AstraZeneca/Medimmune in 2014, Thomas joined the Medimmune Executive Leadership Team in addition to his role as Definiens’ CEO until 2019.
Prior to joining Definiens, Thomas was President and CEO of Barcelona Design. Thomas has worked in the technology industry since 1986, where he has held senior leadership positions for global companies like Documentum, Cadence Design Systems and Siemens AG. Thomas has a successful track record of leading international organizations through strategy development, operational execution and growth from headquarters in Europe and the US.
In addition, Thomas serves as a member of the Supervisory Board of Eppendorf AG and is a member of the Advisory Board of Bayern Kapital.
Thomas holds a Diplom-Ingenieur degree in Electric Engineering and Computer Science from the Technical University in Munich.